ABOUT LINK ALTERNATIF MBL77

Not all individuals with CLL demand therapy. Despite all new innovations, the iwCLL nevertheless recommends watchful observation for patients with asymptomatic disorder.86 This advice is predicated on not less than two randomized trials evaluating observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,